HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anju Ghangurde

Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Set Alert for Articles By Anju Ghangurde

Latest From Anju Ghangurde

Novartis Sheds Vildagliptin Trademark In India Ahead Of Patent Expiry

Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.

Metabolic Disorders Strategy

Cipla's COO Steps Down

Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.

Leadership Strategy

Newbie Remogliflozin Gives Competition A Run For Their Money

Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.

Commercial Strategy

More Top Level Pharma Exits In India As Cipla COO Departs

Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.

 

Companies Leadership

Roche India Head On Way Out

Roche's India head, Lara Bezerra, seen as unconventional in her overall strategic approach, is heading out of the company. Speculation is rife that questions around "business deliverables" may have contributed to the decision.

Commercial Appointments

Biocon And Mylan Prime Pegfilgrastim Expansion

Biocon-Mylan’s sBLA for pegfilgrastim made at a new Indian site gets an FDA go-ahead, facilitating a "multi-fold" scale up in capacity. But it will be interesting to watch how impactful this could be on market dynamics in the US, where more competition has arrived.

Regulation Biosimilars
See All
UsernamePublicRestriction

Register